Market Overview

In A Facebook Post, Martin Shkreli Says He Would Short Immunomedics On Bounce, 'I cant believe they got $250 million for this irinotecan prodrug. The workd has moved on from old chemo mechanisma to targeted/io. That'll be the last 250 they get.'

Partner Center